

Global Pandemic: Another Top 3 Ways to Trade the Virus

The coronavirus just won't die.

In fact, it's only getting worse – again.

“This isn't confined to a handful of states anymore,” says former US FDA Commissioner Dr. Scott Gottlieb. “It's going to be difficult now to get this under control.”

Unfortunately, there's no immediate-term answer on how to stop it.

Johns Hopkins University is warning of another severe breakout. “There is a new wave coming in parts of the country,” Eric Toner, a senior scholar for Health Security said, as quoted by Bloomberg. “It's small and it's distant so far, but it's coming.”

Worse, the World Health Organization just issued a new warning.

“The pandemic is still accelerating,” WHO's director general Tedros Adhanom Ghebreyesus said. “We know that the pandemic is much more than a health crisis, it is an economic crisis, a social crisis and in many countries a political crisis.”

A couple weeks ago, we offered three ways to trade virus, with most turning higher.

On June 17, we highlighted:

Moderna Inc. (MRNA), which is at breakeven at \$63.60
Alpha Pro Tech (APT), which ran from \$13.14 to \$17.55
Teladoc Health (TDOC), which ran from \$189 to \$193.26

We still like all three of those opportunities, especially Moderna Inc., which just advanced its late-stage development of its coronavirus vaccine. Better, it just finalized the Phase 3 study protocol based on feedback from the U.S. FDA.

“We look forward to beginning our Phase 3 study of mRNA-1273 with some 30,000 participants in July,” said Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna. “Moderna is committed to advancing the clinical development of mRNA-1273 as safely and quickly as possible to demonstrate our vaccine's ability to significantly reduce the risk of COVID-19 disease.”

Better, the company and Catalent, Inc., a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna's mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent's biologics facility in Bloomington, Indiana.

However, there are other top ways to trade the virus that just won't die.

Opportunity No. 1 – Inovio Pharmaceuticals (INO)

We've brought INO to your attention a few times, and are again recommending the stock.

Inovio Pharmaceuticals is higher on news of a U.S. contract. In fact, it just received a \$71 million contract from the US Department of Defense to scale up the manufacturing of CELLECTRA 3PSP smart device and the procurement of CELLECTRA 2000 devices, which are used to deliver INO-4800 directly into the skin.



Dr. J. Joseph Kim, INOVIO's President and CEO, said, "INOVIO is very pleased to receive this significant funding from the U.S. Department of Defense to continue our rapid scale-up capacity for our breakthrough DNA medicines delivery device CELLECTRA."

Opportunity No. 2 – Novavax Inc. (NVAX)

Novavax Inc. is up after being awarded a contract by the U.S. Department of Defense (DoD) for the manufacturing of NVXCoV2373, Novavax' COVID-19 vaccine candidate. NVXCoV2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes Novavax' proprietary MatrixM adjuvant.



"JPEO-CRBNB-EB through funding provided by the Defense Health Program, has agreed to fund up to \$60 million to support Novavax in its production of several components of the vaccine that will be manufactured in the U.S. The agreement includes a 2020 delivery of 10 million doses of NVXCoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization (EUA) if approved by the U.S. FDA," according to a NVAX PR.

Opportunity No. 3 – Fiverr International Ltd. (FVRR)

With the pandemic forcing many of us to work from home, Fiverr (FVRR) is thriving.

Fiverr operates an online marketplace worldwide.



Its platform enables sellers to sell their services and buyers to buy them. The company's platform includes approximately 200 categories in 8 verticals, including graphic and design, digital marketing, writing and translation, video and animation, music and audio, programming and technology, business, and lifestyle. Its buyers include businesses of various sizes, as well as sellers comprised of a group of freelancers and small businesses.

Growth is only accelerating for Fiverr, as business around the world hunt for freelancers.

"A lot of businesses are taking this opportunity to move from offline to online. I don't think that this is going away," said CEO Micha Kaufman in a Q1 earnings call. "What we're seeing from our data right now is very consistent with very resilient activity of our customers across all cohorts, including new ones."